{"id":"semaglutide-combined-with-metformin","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1703","moleculeType":"Small molecule","molecularWeight":"165.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a GLP-1 receptor agonist that stimulates insulin release in response to glucose, slows gastric emptying, and promotes satiety. Metformin is a biguanide that reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they provide complementary glucose-lowering effects through different mechanisms.","oneSentence":"Semaglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while metformin decreases hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:07:23.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT06778967","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1100},{"nctId":"NCT07165158","phase":"PHASE4","title":"The Effect of Semaglutide on Bone Health","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-09-15","conditions":"Osteoporosis, Osteoporosis Fracture, T2DM","enrollment":150},{"nctId":"NCT06649344","phase":"PHASE3","title":"A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Type 2 Diabetes","enrollment":884},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT06613854","phase":"PHASE4","title":"Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2024-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":90},{"nctId":"NCT05816057","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","startDate":"2022-07-25","conditions":"Diabetes Mellitus, Type 2","enrollment":476},{"nctId":"NCT02305381","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-12-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":397}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"semaglutide combined with metformin","genericName":"semaglutide combined with metformin","companyName":"The First Affiliated Hospital of Xiamen University","companyId":"the-first-affiliated-hospital-of-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while metformin decreases hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}